Please use this identifier to cite or link to this item:
|Title:||Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation|
|Source:||Chin, C.F., Tian, Q., Setyawati, M.I., Fang, W., Tan, E.S.Q., Leong, D.T., Ang, W.H. (2012-09-13). Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation. Journal of Medicinal Chemistry 55 (17) : 7571-7582. ScholarBank@NUS Repository. https://doi.org/10.1021/jm300580y|
|Abstract:||Platinum(II) anticancer drug cisplatin is one of the most important chemotherapeutic agents in clinical use but is limited by its high toxicity and severe side effects. Platinum(IV) anticancer prodrugs can overcome these limitations by resisting premature aquation and binding to essential plasma proteins. Structure-activity relationship studies revealed a link between the efficacy of platinum(IV) complexes with the nature of their axial ligands, which can be modified to enhance the properties of the prodrug. The existing paradigm of employing platinum(IV) complexes with symmetrical axial carboxylate ligands does not fully exploit their vast potential. A new approach was conceived to control properties of platinum(IV) prodrugs using contrasting axial ligands via sequential acylation. We report a novel class of asymmetric platinum(IV) carboxylates based on the cisplatin template containing both hydrophilic and lipophilic ligands on the same scaffold designed to improve their aqueous properties and enhance their efficacy against cancer cells in vitro. © 2012 American Chemical Society.|
|Source Title:||Journal of Medicinal Chemistry|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 5, 2017
WEB OF SCIENCETM
checked on Nov 16, 2017
checked on Dec 9, 2017
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.